SCHEMBL583069

SCHEMBL583069

CCn1nc(C)c2c(NC3CCCCC3)c(C3=NOC4(C3)CC(C(=O)O)C4)cnc21

nearest known ligand 0.49

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
PDE4B Q07343 10/20 0.42
PDE7A Q13946 1/20 0.42
KMT2A Q03164 1/20 0.33
NR3C1 P04150 3/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 1/20 0.32
TSHR P16473 1/20 0.32
PDE4D Q08499 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL582547 0.95 POLB (0.51) POLBPDE4BPDE7AKMT2A
SCHEMBL583067 0.94 POLB (0.47) POLBPDE4BPDE7A
Bicarbonate SCHEMBL583221 0.93 POLB (0.47) POLBPDE4BPDE7AKMT2ANR3C1
SCHEMBL582541 0.93 POLB (0.48) POLBPDE4BPDE7AKMT2ANR3C1
Bicarbonate SCHEMBL582961 0.92 POLB (0.46) POLBPDE4BPDE7AKMT2ANR3C1
SCHEMBL582381 0.92 POLB (0.47) POLBPDE4BPDE7AKMT2ANR3C1
Bicarbonate SCHEMBL582891 0.92 POLB (0.49) POLBPDE4BPDE7AKMT2ANR3C1
Bicarbonate SCHEMBL583115 0.91 POLB (0.46) POLBPDE4BPDE7AKMT2ANR3C1
SCHEMBL582833 0.91 POLB (0.48) POLBPDE4BPDE7AKMT2A
SCHEMBL582890 0.90 POLB (0.49) POLBPDE4BPDE7AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US claimed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP claimed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US claimed
US-8420666-B2 Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2013-04-16 US disclosed
EP-2124944-B1 Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors RANBAXY LAB LTD (IN) 2012-02-15 EP disclosed
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292196-A1 PYRAZOLO (3, 4-B) PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS PDE3B, PDE4A, PDE3A POLB 1725/4885PDE4B 5/4885PDE7A 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.